** Shares of biopharma firm Travere Therapeutics TVTX.O rise 3.5% to $20.42
** TVTX says it submitted a marketing application to the U.S. FDA for co's drug, Filspari, for treatment of a rare kidney scarring disease called focal segmental glomerulosclerosis
** Co expects to receive regulatory decision in Q2
** Filspari is currently approved to slow decline in kidney function in adults with immunoglobulin A nephropathy, a leading cause of kidney failure
** Up to last close, TVTX has more than doubled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。